Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs LyondellBasell Industries NV — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while LyondellBasell Industries NV trades at $61.84 (market cap $19.76B). The key difference: LyondellBasell Industries NV is far larger — about 2.2× Kymera Therapeutics Inc. Common Stock's market cap, and LyondellBasell Industries NV pays a 4.51% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and LyondellBasell Industries NV for 88 Days on average.
| KYMR | LYB | |
|---|---|---|
Market Cap | $8.87B | $19.76B |
Volume | 779,107 | 2,519,506 |
Sector | Health | Basic Materials |
52-Week High | $127.31 | $82.38 |
52-Week Low | $55.80 | $42.28 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $8.26B | $31.35B |
Dividend Yield | — | 4.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LYB trades at $60.01, up 1.01% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue declined to $30.15B in 2025, with a net loss of $745M, though Q2 2026 EPS beat expectations at $4.30. The company maintains a dividend payout, with a consensus analyst price target of $68.56. Cash flow from operations improved to $2.26B in 2025, but debt-to-asset ratio rose to 38.18%.
Outlook is mixed: analyst consensus is evenly split between Buy and Hold, with potential upside to the price target, but risks include declining revenue, negative profit margins, and high debt. Recent news highlights dividend sustainability concerns in the chemical sector, though some analysts see earnings recovery potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
